TAK-778

• Description :

  TAK-778 is a derivative of ipriflavone and has been shown to induce bone growth in in vitro and in vivo models.

• UNSPSC :

  12352005

• Hazard Statement :

  H302

• Target :

  Drug Derivative; IGF-1R; MMP; Phosphatase; TGF-β Receptor

• Type :

  Reference compound

• Related Pathways :

  Metabolic Enzyme/Protease; Others; Protein Tyrosine Kinase/RTK; TGF-beta/Smad

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/TAK-778.html

• Solubility :

  10 mM in DMSO

• Smiles :

  O=C(NC1=CC=C(CP(OCC)(OCC)=O)C=C1)[C@@H](C2)S[C@@H](C)C(C3=C2C=C4OCOC4=C3)=O

• Molecular Formula :

  C24H28NO7PS

• Molecular Weight :

  505.52

• Precautions :

  P264-P270-P330-P501

• References & Citations :

  [1]Rosa AL, et al. TAK-778 enhances osteoblast differentiation of human bone marrow cells via an estrogen-receptor-dependent pathway. J Cell Biochem. 2004 Mar 1;91 (4) :749-55.|[2]Notoya K, et al. Enhancement of osteogenesis in vitro and in vivo by a novel osteoblast differentiation promoting compound, TAK-778. J Pharmacol Exp Ther. 1999 Sep;290 (3) :1054-64.|[3]Cai M, et al. TAK-778 induces osteogenesis in ovariectomized rats via an estrogen receptor-dependent pathway. J Bone Miner Metab. 2011 Mar;29 (2) :168-73.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• CAS Number :

  [180185-61-9]